fbpx

Safilo and Missoni Announce Multi-Year Renewal of Global Eyewear Licensing Agreement

Missoni Eyewear
Missoni Eyewear

Safilo Group and Missoni announce the renewal of their global licensing agreement for Missoni brand eyewear until the end of 2029.

Since the start of the relationship in 2020, Missoni has represented a significant brand in Safilo’s women’s luxury fashion portfolio thanks to its collections characterized by the innovative use of the fashion house’s iconic textiles and colours, giving them a distinctive identity.

This style fully expresses the authenticity of the brand’s DNA making the Missoni eyewear collections immediately recognizable and unique.

“We are very proud to renew our partnership with Missoni. In only four years of collaboration, we have been able to strongly develop the eyewear category, in particular in the main European markets and in North America. This renewal offers us a new and stimulating opportunity to consolidate and broaden our distribution, continuing to work together with the brand.”

Angelo Trocchia, CEO of Safilo Group

Missoni Eyewear
Missoni Eyewear

We are glad to announce the renewal of our partnership with Safilo until 2029. The construction of lasting and solid relationships with our partners is, for us, a fundamental priority, as it allows us to develop high- quality projects that can lead to long-term success. During these past four years, the significant contribution of the eyewear category has been one of the driving factors of our growth that will further benefit from this agreement in the upcoming future.

Livio Proli, CEO of Missoni Spa

Click HERE for the press release.

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!

Featured Posts

Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read More
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read More
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read More
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read More
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more